Rationale: Acute kidney injury (AKI) has a high prevalence and mortality in critically ill patients. It is also a powerful risk factor for heart failure incidence driven by hemodynamic changes and neurohormonal activation. However, no drugs have been approved by the Food and Drug Administration. Endogenous pGC-A (particulate guanylyl cyclase A receptor) activators were reported to preserve renal function and improve mortality in AKI patients, although hypotension accompanied by pGC-A activators have limited their therapeutic potential.
A cute kidney injury (AKI) is a syndrome of impaired renal function, characterized by a reduction of glomerular filtration rate (GFR) or urine output. 1, 2 It has an overall frequency of 6% in community-acquired and hospital-acquired subjects and is especially common in critically ill patients admitted to intensive care units, with a frequency of 57%. 3, 4 Notably, AKI is a common complication after cardiovascular surgery such as coronary artery bypass grafting and aortic repair, ranging from 13% to 43%, depending on the definition of AKI. [5] [6] [7] Further, hypotension and decreased renal perfusion also plays a key role in initiating AKI in the surgical setting. In a contemporary matched cohort of 146 941 hospitalized adults, 31 245 (21%) experienced AKI. Importantly, the study observed that AKI was independently associated with a higher risk for heart failure (HF) after discharge. 2 Despite increasing prevalence of AKI with high mortality and high risk for HF, no drugs for AKI have been approved by the Food and Drug Administration.
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Both ischemia and hypovolemia have been implicated in mediating AKI through activation of pathways of cellular injury and death. Indeed, one mechanism for AKI as well as the increased risk for HF is activation of intrarenal and circulating inflammatory cytokines and deleterious hormones such as Ang II (angiotensin II). Notably, experimental AKI and transition to chronic kidney disease is reduced with AT1R (Ang II receptor type 1) blockade before the onset of ischemic AKI. 8 Moreover, recent studies have also reported that Ang II and the AT1R mediate intrarenal inflammation in models of AKI. 8, 9 Additionally, renal cell apoptosis has emerged as an underlying final pathway contributing to AKI initiation and associated decline in GFR. 10 CRRL269 is a novel designer NP (natriuretic peptide), which was engineered at the Mayo Clinic as an innovative peptide targeting the renocardiac protective pGC-A (particulate guanylyl cyclase A receptor) which synthesizes the second messenger cGMP. 11 Importantly, CRRL269 is a selective pGC-A activator with minimal pGC-B (particulate guanylyl cyclase B receptor) activity. 11 Activation of pGC-A is associated with inhibition of cell apoptosis, suppression of inflammatory cytokines, diuresis, and natriuresis, induction of endothelial regeneration, and antiremodeling with inhibition of the renin-angiotensin system (RAS). [12] [13] [14] [15] [16] [17] [18] Specifically, CRRL269 represents a chimeric peptide that integrates key amino acids from URO (urodilatin, a renal-derived peptide) with key amino acids from BNP (B-type NP, a cardiac derived peptide).
11 CRRL269 possesses enhanced renoprotective properties such as diuresis, natriuresis, and increase in GFR compared with native pGC-A activators such as BNP or URO while retaining RAS-suppressing properties with less hypotension. Indeed, CRRL269 mediated superior renal pGC-A activation in vitro and renal protective properties in vivo compared with the 2 respective NPs. Mechanisms for its enhanced renal actions are because of increased resistance to neprilysin degradation and RAS suppression. 11 The mechanism of blood pressure (BP) preservation was due to reduced arterial relaxation and greater cardiomyocyte cAMP generation. 11 Although it is known that NPs induce vasorelaxation via suppression of intracellular Ca 2+ in vascular smooth muscle cells (VSMC), 19, 20 the action of CRRL269 on Ca 2+ levels in VSMC remains undefined.
Given the renoprotective properties of CRRL269 and the need for Food and Drug Administration-approved therapies targeting AKI, here we investigated for the first time the renocardiac protective and RAS-suppressing actions of CRRL269 in a large animal model of ischemic AKI produced by the clinically relevant maneuver of aortic cross clamping (ACC) simulating surgical aortic repair. 21 This included assessing CRRL269-mediated increases in plasma, urinary, and renal cGMP. We also sought to define in vitro the role of renal apoptosis in ischemic AKI and the ability of CRRL269 to attenuate cell death compared with BNP and ANP (atrial NP). Additionally, we defined the role of PKG as a mediator of the antiapoptotic actions of CRRL269. We also explored the molecular mechanism of CRRL269's BP preservation through the actions of CRRL269 on intracellular Ca 2+ levels in VSMC. Lastly, we assessed uCNP (urinary C-type NP) as a biomarker for AKI based on our previous findings in human HF cohorts and aged animals. What New Information Does This Article Contribute?
• A innovative designer pGC-A activator CRRL269 preserved renal function and exhibited cardiac protection, without causing hypotension in a large animal model of AKI.
• Its beneficial actions were mediated, at least in part, by antiapoptosis and reduced calcium suppression.
• We also reported that uCNP (urinary CNP) may serve as a biomarker for identifying AKI.
Native pGC-A activators have the potential to treat AKI because of their renal and cardiac protective actions. However, native activators inevitably reduce blood pressure, which may reduce renal perfusion pressure and thereby compromise their renal function enhancement. Here we employed a novel pGC-A activator, CRRL269, which we previously documented possessed superior renal protective effects than native activators, in a large animal model of AKI in canines. We reported that CRRL269 significantly improved renal function compared with vehicle treatment, with less kidney injury, renal apoptosis while importantly maintaining the blood pressure. We also reported for the first time that uCNP was elevated markedly during AKI and thus may represent a novel biomarker for AKI. Taken together, our results support the development of CRRL269 for the treatment of AKI.
Methods
Studies were performed in accordance with the Animal Welfare Act and with approval of the Mayo Clinic Institutional Animal Care and Use Committee (IACUC protocol number: A00002722).
The authors declare that all supporting data are available within the article (and its online supplementary files in the Online Data Supplement).
Ischemic AKI in Canines
An ischemic AKI model in normal mongrel canines (male, 25-30 kg; age, 1-2 years old; n=5 per group, Twin Valley Kennel) was created with high dose intravenously indomethacin infusion (10 mg/ kg with NaHCO 3 [5 mg/kg] dissolved in 50 mL distilled water) followed by suprarenal ACC as described previously. 21 The number of animals in each group was defined by a priori power calculation considering a statistical power of 80% and α=0.05. We used male canines only to minimize the experimental variation of the outcomes of ischemic AKI, and we plan to recruit both male and female patients in our future clinical trials. Briefly, canines were anesthetized with intravenous pentobarbital (15-30 mg/kg) and fentanyl (4-12 µg/kg), intubated and mechanically ventilated on air with supplemental oxygen, 3 L/min, 12 cycles/min (Harvard Apparatus, Millis, MA). Both femoral artery and carotid artery were accessed for mean arterial pressure monitoring and blood sampling. The femoral vein was cannulated for continuous inulin infusion and saline/indomethacin/drug infusions. The left renal artery was attached with a probe for renal blood flow (RBF) measurement, and a catheter was placed in the left ureter for passive urine collection. A flow-directed balloon-tipped thermodilution catheter was advanced to the pulmonary artery through the external jugular vein for measurement of cardiac filling pressures and cardiac output. After 60 minutes equilibration, baseline characteristics were established. A 45-minute infusion of indomethacin was then started. A Blalock clamp was applied at the level of the suprarenal aorta ACC to occlude blood flow to 2 kidneys. ACC was maintained for 60 minutes, and 16.3 pmol/kg per min CRRL269 or vehicle (0.9% saline) infusion was initiated 5 minutes before releasing the clamp. Dogs were randomized to receive CRRL269 or vehicle infusion. Investigators were not blinded to treatments, but biochemical analysis was performed by technicians who were blinded to treatment. The dose of CRRL269 was chosen based on ANP dose used in our previous AKI study, 21 and it is a medium dose between low and high doses we investigated in our previous study in normal canines. 11 Drug infusion lasted for 120 minutes and data/samples were collected every 30 minutes, termed as clearance 1 (CL1), clearance 2 (CL2), clearance 3 (CL3), and clearance 4 (CL4). Immediately after completion of CL4, the animal was euthanized , left kidney was harvested, sliced, and preserved in 10% formalin solution, or slices were snap-frozen with liquid nitrogen. GFR values were calculated based on inulin clearance. Urinary sodium was measured with pHOx Ultra (Nova Biomedical, Waltham, MA). Dogs were included in the study based on the effectiveness of renal aortic clamping, which was demonstrated by the marked elevation of mean arterial pressure and lack of urine output. One dog was euthanized early as a result of severe blood loss after unclamping of the aorta, which was torn by the surgical clamp, and therefore was excluded from the analysis.
Hormonal Measurements
Plasma and urinary cGMP were measured with commercially available ELISA kits (Enzo Life Sciences, Farmingdale, NY). Ex vivo renal parenchyma cGMP levels were measured with the same ELISA kits. Approximately 0.1 g frozen canine renal cortex or medulla (n=5 Veh, n=4 CRRL269) were homogenized with 2 mL of 0.1 N HCl by a homogenizer (Polytron PT1200E, Fisher Scientific, Waltham, MA). Homogenates were subjected to 600g 10-minute centrifugation, and supernatants were collected for cGMP assay. Final cGMP levels were adjusted by protein concentration measured by BSA method. Plasma Ang II was measured by radioimmunoassay (Phoenix pharmaceuticals, Burlingame, CA). Plasma and uCNP was measured by CNP radioimmunoassay (Phoenix pharmaceuticals, Burlingame, CA). Both ELISA and radioimmunoassay were performed as instructed by the manufacturers' protocols.
Histology and TUNEL Analysis
Fixed renal tissues were embedded with paraffin and sliced. For histology analysis, paraffin-embedded slides in vehicle (n=5) and CRRL269 (n=5) were stained with hematoxylin and eosin. A renal pathologist who is blinded to the study examined the hematoxylin and eosin staining slides. Renal morphological injury such as tubular dilation and vacuolization was evaluated. Renal cortical apoptosis in vehicle (n=5) and CRRL269 (n=5) dogs was assessed with TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling) assay (Promega, Madison, WI) following the protocol provided by the manufacturer. Normal canines (n=4, same background as the canines used in the current study) that did not undergo AKI or any other surgeries were added as an additional group to evaluate the renal apoptosis. DAPI (Vectashield, Vector Laboratories, Burlingame, CA) was used to label the nucleus. TUNEL results were analyzed by confocal fluorescence microscopy (Nikon A50R, Melville, NY).
Oil Immersion Induced Hypoxia/Reoxygenation In Vitro
Human primary renal proximal tubular epithelial cells (HRPTC, ScienCell Research Laboratories, Carlsbad, CA) were seeded in 96-well plates and cultured for 1 day until 70% to 80% confluency before experiments. Passages 3 to 5 were used. Caspase 3/7 green apoptosis assay agent (Essen BioScience, Ann Arbor, MI) was added to culture medium for the detection of apoptosis. Plates were then transferred to a time-lapsed, live imaging system IncuCyte (Essen BioScience, Ann Arbor, MI) for apoptosis monitoring for a total of 24 hours. Hypoxia/reoxygenation (H/R) in cells was mimicked with mineral oil (Sigma, St Louis, MO) immersion. 25 Cells were immersed with oil for 2 hours, washed twice, and replaced with fresh medium including vehicle (H/R group) or drugs. ANP, BNP, CRRL269 at concentrations of 10 mol/L CRRL269 was added. Cells without H/R stimulation were labeled as negative control group. Apoptosis signals (eg, apoptosis object counts) were analyzed with the software provided by IncuCyte.
Apoptosis Pathway PCR Array and Caspase7 Real Time PCR
Two groups of HRPTC (vehicle and 10 −6 M CRRL269) that underwent oil-induced H/R stress as described above were grown in 6-well plates, and total RNA were collected with the Trizol method (Thermo Fisher Scientific, Waltham, MA). RNA was then reverse transcribed for cDNA for polymerase chain reaction (PCR) RT2 array experiment. Apoptosis pathway PCR array (Qiagen, Germantown, MD) was then conducted with the SYBR green (Bio-Rad Laboratories, Hercules, CA) method in Lightcycler 480 (Roche Diagonostics, Indianapolis, IN). Raw data were analyzed with online Qiagen RT2 PCR analysis program. The Caspase7 gene was upregulated by H/R and downregulated by CRRL269 both at least 2-fold and was selected for RT (real time)-PCR verification. Caspase7 RT-PCR primer (PPH00110C-200, Qiagen, Germantown, MD) was obtained, and RT-PCR reactions were performed with SYBR green method. B2M gene (PPH01094E, Qiagen, Germantown, MD) was used for normalization.
Measurements of Intracellular Calcium in VSMC
Human primary aortic vascular smooth cells (ScienCell Research Laboratories, Carlsbad, CA) were cultured and maintained as instructed by the manufacturer, and cells at passage 4 or 5 were used. Calcium imaging was performed as previously described. 26 Briefly, cells were seeded on a 25 mm round cover glass (Fisher Scientific, Pittsburgh, PA) with a density of 5×10 4 cells per slide. These glass slides were pretreated with 0.5 N NaOH for 8 hours, rinsed with water, and sterilized before use. After overnight culturing, the glass with the cells was assembled in a MS-502 Chamber (ALA Scientific Instrument, Farmingdale, NY) and loaded with 3 μM fura-2 AM (Invitrogen, Carlsbad, CA) for 30 minutes at a 37°C incubator. The chamber was then placed on the stage of an inverted Olympus IX71 microscope (Olympus America Inc, Waltham, MA). The cells were maintained in 1 mL human primary aortic vascular smooth cells medium and pretreated with or without ANP, BNP, or CRRL269 at concentration of 10 −9 or 10 −7 mol/L for 5 minutes before perfused with 5 mL medium containing Ang II (10 −8 or 10 −7 mol/L). The intracellular Ca 2+ fluorescence signals were measured as a ratio of fluorescence intensities at 510 nm from excitations of 340/380 nm using a Hamamatsu ORCA-R2 CCD camera with a Sutter LB-LS/17 light source. Baseline fluorescence was recorded after 5 minutes of pretreatment, and fluorescence images were acquired continuously during the Ang II perfusion. Background fluorescence was subtracted and the calcium signal (F) was normalized to baseline fluorescence (F0) and expressed as a ratio (F/F0) using MetaFluor software (Olympus America Inc, Waltham, MA).
Statistics and Data Analysis
Data were expressed as means±SEM, and significance analysis was performed with Prism 7 (Graphpad, La Jolla, LA). Data normality was assessed with Shapiro-Wilk test. For normally distributed data, 1-way ANOVA and 2-way ANOVA were used in the in vivo and in vitro studies in which multiple time points were involved, and 2-tailed t tests were used for comparisons between 2 groups. Nonparametric Mann-Whitney test was applied for data that were not normally distributed.
Results

Ischemic AKI Hormonal and Renal Function In Vivo in Canines
In vivo, continuous infusion for 2 hours with CRRL269 increased plasma, urinary, and renal parenchyma cGMP levels consistent with pGC-A activation ( Figure 1A through 1C) . Results in vivo were presented as changes from baseline. Compared with vehicle, CRRL269 treatment markedly elevated cGMP values from CL1 to CL4. Notably, AKI induced by ACC greatly stimulated plasma Ang II levels compared with baseline. CRRL269 inhibited plasma Ang II levels ( Figure 1D ). Specifically, in vehicle group, Ang II levels remained high during postischemia phases from CL1 to CL4, while CRRL269 infusion significantly reduced circulating Ang II levels.
With ACC occluding suprarenal aorta, GFR was markedly reduced during ACC and changes from baseline results are shown in Figure 2A . A marked reduction of RBF was also observed as reported in Figure 2B during ACC. Importantly during postischemia phases, CRRL269 maintained GFR and RBF, while vehicle did not preserve these 2 renal hemodynamic parameters (Figure 2A and 2B) . Similarly, urine output and urinary sodium excretion (UNaV) were reduced by ACC, whereas CRRL269 significantly induced diuresis and natriuresis compared with vehicle, which is consistent with the renal protective actions observed with GFR and RBF ( Figure 2C and 2D) . Figure 3A) , indicating CRRL269 is not a hypotensive agent, and a similar trend was observed in cardiac output ( Figure 3B ). Right atrial pressure and pulmonary capillary wedge pressure were also markedly elevated during renal ischemia, of which CRRL269 reduced right atrial pressure and pulmonary capillary wedge pressure after ischemia ( Figure 3C and 3D) . The results of cardiovascular function parameters support CRRL269 reduced cardiac filling pressure without a hypotensive response.
Renal Injury Ex Vivo Analysis
Hematoxylin and eosin staining indicated that CRRL269 group presented with less vacuolization compared with vehicle, which is consistent with less renal injury ( Figure 4A and 4B) . Additionally, ischemia/reperfusion markedly increased renal cortical apoptotic cell death compared with normal canine kidneys, as illustrated by TUNEL assay using confocal microscopy ( Figure 4C and 4D) . Apoptotic cells were mostly tubular epithelial cells and glomerular mesangial cells. Importantly, CRRL269 treatment reduced apoptosis in the renal cortex in comparison with vehicle.
H/R Mediated Apoptosis in HRPTC
Recognizing the antiapoptosis observed in renal tubular cells ex vivo by CRRL269, we used HRPTC to investigate H/R-induced apoptosis in vitro with a time-lapsed and live imaging system. Here, H/R markedly stimulated apoptosis in HRPTC as evidenced by the sharp increase of apoptotic signals 2 hours after reoxygenation initiated, in comparison with the negative control group (Figure 5A through 5C ). CRRL269 at concentrations 10 −7 and 10 −6 mol/L significantly reduced apoptotic signals compared with the H/R group alone. More importantly, CRRL269 induced more robust antiapototic effects compared with ANP, and a trend of superiority was observed in comparison with BNP ( Figure 5A ). We next found PKG-specific analog, 8-pCPT-cGMP, at concentrations of 10 −6 and 10 −5 mol/L mimicked the apoptosis inhibition observed with pGC-A activators ( Figure 5B ). Furthermore, PKG inhibitor KT-5823 abrogated the antiapoptotic effects induced by CRRL269 ( Figure 5C ). In the human apoptosis pathway gene array, 33 out of 84 genes in the apoptosis pathway were upregulated at least 2-fold by H/R stimulation. In contrast, 8 out of 84 genes (CASP7, FADD, CRADD, DAPK1, HGDC, BCL2L11, BIK, and TNFRSF1A) were downregulated at least 2-fold by CRRL269 treatment ( Figure 5D ). Caspase7 gene (top gene, upregulated in H/R, and downregulated in CRRL269) was chosen to be verified by RT-PCR because of its critical function mediating apoptosis, and our results support that H/R increased Caspase7 gene by 1.89-fold and CRRL269 treatment significantly reduced its expression level to 1.25 ( Figure 5E ). 
CNP as a Compensatory Biomarker for AKI
We found plasma and urinary CNP levels increased starting from the AKI reperfusion phase, with elevation in urinary CNP being more pronounced ( Figure 7A and 7B). Infusion with CRRL269 increased urinary CNP levels compared with vehicle.
Furthermore, with RT-PCR, cortical CNP gene (NPPC) expression levels, although lower compared with medullary expression, were elevated by CRRL269 treatment (Online Figure IA) . In vitro, human glomerular microvascular endothelial cells presented considerably lower NPPC mRNA levels than tubular cells HRPTC (Online Figure IB) . Additionally, CNP treatment at 10 −7 mol/L suppressed human renal fibroblast proliferation (Online Figure IC ).
Discussion
The current study was designed to advance the therapeutic potential of CRRL269, a novel pGC-A activator, for the treatment of AKI with a special focus on studies in a large animal model with high clinical relevance. The major findings of our study are that CRRL269 exerted renal protective actions in canine model of AKI post-ischemia/reperfusion for 2 hours with GFR and RBF preservation, enhanced diuresis and natriuresis, and reduced renal cortical vacuolization and suppression of Ang II without inducing hypotension. This occurred in the setting of CRRL269-mediated increases in plasma, urinary, and renal tissue cGMP. Moreover, CRRL269 reduced cardiac filling pressures such as right atrial pressure and pulmonary capillary wedge pressure. Further, CRRL269 reduced apoptosis in the kidney cortex in our AKI model. In vitro, CRRL269 exerted more robust antiapoptotic effects in human renal tubular cells and less intracellular Ca 2+ suppression in arterial vascular smooth muscle cells, compared with native pGC-A activators and also attenuated H/R-mediated gene upregulation of apoptotic pathways. Additionally, we established that urinary CNP may be a novel biomarker for AKI. Taken together, our results support CRRL269 as a promising novel AKI drug.
The lack of use of large animal models of AKI has, in part, limited successful drug discovery in AKI as rat and mice models, compared with canine or porcine models, lack the high functional similarity and hemodynamics profiles common to humans. Further, use of small animal models is also complicated by the difficulty in measuring key hemodynamic data during and after induction of AKI. 28, 29 We incorporated a large animal model in our study, which highly mimics ischemiainduced AKI in the clinical setting resulting from suprarenal ACC that is highly relevant to vascular surgical reconstruction of the aorta and renal arteries. In this model, CRRL269 infusion was started after ischemia and before reperfusion and resulted in renoprotection, which corroborated with the in vitro apoptosis experiments thus confirming and extending previous studies in large animal models. 21, 30, 31 Specifically, ACC in canines in the presence of inhibition of vasodilating prostaglandins induced reductions in GFR in association with renal vasoconstriction with tubular vacuolization and marked increase in apoptotic cell death. Though the duration of the study was short and physiological parameters were only collected 2 hour postischemia, we observed moderate loss of GFR, which is in line with published studies in AKI long-term studies such as postischemia for 48 hours. 32, 33 We believe the promising results obtained from this short-term study will guide us in the design of more long-term studies, such as 2 or 7 days postischemia AKI, to evaluate CRRL269's therapeutic potential more extensively.
Importantly, CRRL269 treatment improved renal function highlighted by GFR preservation and enhanced renal excretory actions in vivo. The enhanced renal actions occurred in the absence of hypotension. The maintenance of BP is especially useful for the safety, therapeutic potential, and renal functional preservation in human clinical studies in AKI patients. 34 Indeed, it was demonstrated that a reduction in renal perfusion pressure leads to abolished natriuretic effects stimulated by ANP administration in rodents, implicating the importance of maintaining BP in pGC-A therapeutics. 35 A decrease of cardiac filling pressures without significant hypotension would lead to an increase in transrenal perfusion pressure and consequently improve renal function. CRRL269 retains its ability to reduce cardiac filling pressures, consistent with our previous report in normal canines. 11 The reduction of right atrial pressure and pulmonary capillary wedge pressure could be due to the decrease of intravascular volume in view of the markedly greater increase in diuresis and natriuresis with CRRL269 treatment in the presence of AKI. Importantly and in contrast to endogenous pGC-A activators such as BNP, CRRL269 was not associated with hypotension. 11 Here we report that a key mechanism of the more preserved BP is, at least partially, mediated by less intracellular Ca 2+ suppression in VSMC stimulated by Ang II in the presence of CRRL269. These data complement the potential enhanced positive cardiac inotropic effects secondary to our findings of cAMP increases in cardiomyocytes and reduced arterial relaxing effects observed previously. 11 However, future in-depth studies are warranted to elucidate this novel CRRL269 modulation of intracellular Ca 2+ levels. In AKI, neurohormonal pathways such as RAS activation are suggested to induce cardiac structural changes and dysfunction. 36 The pathophysiological consequences by RAS activation include cardiac hypertrophy, fibrosis, inflammation, and apoptosis, which further result in cardiac dysfunction Figure 7 . C-type natriuretic peptide (CNP) changes by CRRL269 in acute kidney injury. A, Plasma CNP, n=5 each group, #P<0.05 vs vehicle using 2-way ANOVA followed by Bonferroni post hoc test, *P<0.05 vs baseline (BL) using 1-way ANOVA followed by Dunnett post hoc test. B, urinary CNP, statistics same as plasma CNP. Data were presented as absolute changes from baseline. Experimental schedule was described in Figure 1 legend. ACC indicates aortic cross clamping; CL1, clearance 1; CL2, clearance 2; CL3, clearance 3; CL4, clearance 4; and INDO, indomethacin.
and HF. Studies reported that plasma Ang II was significantly increased in ischemic AKI, and more importantly, ACEi (angiotensin converting enzyme inhibitor) administration was shown to attenuate the initiation and progression of myocardial dysfunction and remodeling in animal models and patients. [37] [38] [39] Thus, these previous results were not surprising given the enormous cardioprotective effects induced by ACEi and anti-RAS drugs in the treatment of HF. Thus a promising therapeutic agent suppressing RAS especially Ang II activation is critical for the protection of cardiac function in AKI. In our current study, CRRL269 suppressed plasma Ang II levels, hence supporting the potential of cardioprotection in the setting of AKI.
Lines of evidence support that the pGC-A/cGMP signaling pathway plays a critical role maintaining renal physiological integrity and protecting the kidney from injury. [40] [41] [42] [43] [44] One of the key pathophysiological pathways targeted by pGC-A is apoptosis. Repeated studies have established that apoptosis is a key feature of AKI, although drugs targeting apoptosis have not been effective in preventing AKI. 45 Recognizing the critical role of ischemia/reperfusion-induced apoptosis in tubular cells in our in vivo AKI model, we used an in vitro model of acute H/R-mediated apoptosis in tubular cells to investigate the molecular mechanism of CRRL269's renal protective action. CRRL269 showed superior antiapoptotic actions compared with ANP, and we demonstrated that this property is mediated by the cGMP/PKG pathway illustrated by a PKG-specific cGMP analogue and a PKG inhibitor. Further, CRRL269 suppressed apoptotic genes expression with PCR array analysis. Moreover, RT-PCR demonstrated downregulation of Caspase7, which is important in cell apoptosis execution, by CRRL269 in HRPTC thus providing useful evidence for inhibition of renal cell apoptosis through activation of pGC-A/ cGMP signaling by CRRL269 in vivo. Indeed, in vivo, we observed robust increases in plasma, urinary, and renal tissue cGMP. The superior antiapoptotic effects of CRRL269 observed in vitro support its direct cytoprotective effect, which is independent of its beneficial effects on renal hemodynamics. Further studies on the underlying molecular mechanism of CRRL269 renoprotective effects such as PKG substrates (eg, cell survival related protein-Akt) phosphorylation are warranted.
Biomarkers such as NGAL (neutrophil gelatinase-associated lipocalin) and KIM-1 (kidney injury molecule 1) have been used for AKI early prediction and prognosis. 46, 47 However, the use of current biomarker profiles in the clinic has been limited by the specificity and predictive power signified by the average or low AUCs. 48 Novel biomarkers providing an early detection of AKI immediately after injury insult are needed. In our laboratory, we previously documented that CNP is present in the kidney and is predominantly distributed in proximal, distal tubules and collecting ducts, and not in glomeruli. 24, 49, 50 Urinary CNP was previously reported to predict patient outcomes in acute decompensated HF, which was superior compared with KIM-1 or NGAL. 22 Furthermore, it was suggested that in subjects with impaired renal function, uCNP was increased. 51 In the current study, we explored, for the first time, the biomarker potential of uCNP in AKI, and we showed that uCNP was markedly elevated by ischemia/ reperfusion. Notably, CRRL269 treatment increased uCNP and renal CNP gene expression levels, which is consistent with the report of in vitro CNP mRNA and protein increases by native pGC-A activators. 52 We also confirmed CNP's renal protective effects in which CNP suppressed renal fibroblast proliferation in vitro. It is thus interesting to speculate if the renoprotective actions of CRRL269 may, in part, be also secondary to actions of CNP.
Our study is a pilot, short-term study assessing the renocardiac protective actions of CRRL269 in AKI canines. The current study also advances the understanding of pathophysiological changes caused by AKI, such as apoptosis and renal dysfunction. Our study has limitations as we only assessed the acute effects of CRRL269 in AKI. Specifically, its renoprotective effects in intermediate and long-term periods were not investigated in the current study. Thus, further studies in more long-term model models of AKI are warranted with the use of CRRL296 to evaluate if its renal protective actions are sustained. As described above, renal and cardiac function assessment conducted in 2 or 7 days post-ischemia/reperfusion in AKI model to further confirm CRRL269's sustained renocardiac protection and rule out the possibility of a merely transient improvement by CRRL269 observed in the present study is warranted. Additionally, a preventive strategy with CRRL269 infusion before ischemic insult is warranted to explore its potential as a drug for AKI prevention. Moreover, it is important to assess the protective actions of CRRL269 in other models of AKI such as nephrotoxic drug induced AKI to explore its potential in a wider scope given the heterogeneity observed in the AKI patient population.
Given no drugs have been approved for AKI treatment by the Food and Drug Administration and the connection between the heart and kidney, there is an unmet need for the development of innovative drugs to preserve the kidney function directly and in the meantime protect the heart in the setting of AKI. The connection between the heart and kidney requires single agents targeting both organs thus treating cardiorenal syndrome. Recognizing the renocardiac protective effects of CRRL269 in AKI canines, we believe it may have translational potential for the treatment of AKI as well as HF prevention.
